All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Visual Abstract | Efficacy and safety of spesolimab in the prevention of generalized pustular psoriasis flares: Effisayil 2
Bookmark this article
Dysregulation of interleukin 36 plays a key role in the pathogenesis of generalized pustular psoriasis (GPP), which has a highly unpredictable clinical course. Spesolimab, an anti-interleukin-36 receptor antibody, is approved for the treatment of flares in adult patients with GPP; however, there are currently no optimal treatments for the prevention of GPP flares.
The Psoriasis and Psoriatic Arthritis Hub has previously reported safety results from Effisayil 1 (NCT03782792) assessing spesolimab in patients with GPP presenting with an acute flare. More recently, Morita et al.1 published an article in Lancet reporting results from Effisayil 2 (NCT04399837) evaluating the efficacy and safety of subcutaneous spesolimab for the prevention of flares in patients with GPP. Here, we are pleased to present a visual abstract summarizing the key findings.
Key baseline patient characteristics are shown in Table 1.
Table 1. Baseline patient characteristics*
|
Characteristic, % (unless otherwise stated) |
Spesolimab (N = 92) |
Placebo (n = 31) |
||
|---|---|---|---|---|
|
|
Low (n = 31) |
Medium (n = 31) |
High (n = 30) |
|
|
Mean age, years |
38.9 |
42.9 |
40.2 |
39.5 |
|
Sex |
|
|
|
|
|
Female |
65 |
65 |
60 |
58 |
|
Male |
35 |
35 |
40 |
42 |
|
Mean GPPASI total score |
3.03 |
3.12 |
3.92 |
3.11 |
|
GPPGA total score |
|
|
|
|
|
0 |
6 |
26 |
10 |
13 |
|
1 |
94 |
74 |
90 |
87 |
|
Mean PSS total core |
4.1 |
3.9 |
5.3 |
3.6 |
|
Mean DLQI total score |
7.6 |
6.6 |
11.1 |
7.2 |
|
Concurrent plaque psoriasis† |
32 |
23 |
23 |
32 |
|
Use of at least one systemic medication (discontinued at randomization) |
81 |
74 |
73 |
71 |
|
Mean number of previous flares/year |
2.7 |
1.9 |
2.4 |
2.4 |
|
Time since first diagnosis |
|
|
|
|
|
≤1 year |
16 |
13 |
13 |
10 |
|
>1 to ≤5 years |
19 |
29 |
30 |
32 |
|
>5 to ≤10 years |
19 |
26 |
27 |
23 |
|
>10 years |
45 |
32 |
30 |
35 |
|
DLQI, Dermatology Life Quality Index; GPPASI, Generalized Pustular Psoriasis Area and Severity Index; GPPGA, Generalized Pustular Psoriasis Physician Global Assessment; PSS, Psoriasis Symptom Scale. |
||||
The results from this study demonstrated that high-dose spesolimab was superior to placebo and significantly reduced the risk of a GPP flare over 48 weeks. Spesolimab has the potential to shift the clinical management of GPP, leading to improvement in patient’s quality of life.
- Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402(10412):1541-1551. DOI: 1016/S0140-6736(23)01378-8
More about...
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox